We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be attending the American Intellectual Property Law Association (AIPLA) 2026 Spring Meeting. She will also be participating as a speaker at the AIPLA Chemical Patent Practice Institute, presenting on the China perspective at an international panel on written description. The Chemical Patent Practice Institute will take place from May 11 to 12, while the Spring Meeting will take place from May 13 to 15, 2026, at the historic Fairmont San Francisco.

As one of the most significant gatherings for intellectual property professionals in North America, the AIPLA Spring Meeting is a hub for high-level discussion on the legislative and judicial trends shaping the future of IP. This year's program highlights the intersection of innovation and technology, with a deep focus on "The Future of IP in an AI-Driven World."

If you or your firm will be in San Francisco for AIPLA2026, Jennifer would be delighted to meet to discuss cross-border patent strategies or our specialized services in China. Please reach out to us to schedule a meeting during the conference.

我們過去活動

Jennifer Che Once Again Named to the IAM Strategy 300

2026年8月21日

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

2026年7月22日

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2026年6月2日

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

2026年5月8日

Recommended Insights

Thin Disclosure but "Bulletproof" Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data

2026年1月8日
In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors. Other “follow-on” IP, such as those directed towards formulations, polymorphs, and salt forms, are often regarded as less likely to survive invalidation challenges, especially in China where the standard of “person skilled in the art” is so […]
閱讀更多 >

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

2024年2月28日
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]
閱讀更多 >

Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement

2024年1月9日
Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]
閱讀更多 >

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
閱讀更多 >
Top crossarrow-right